‹ All episodes

The BioInsights Podcast

Insights into advanced therapies in the context of evolving funding and M&A environments

June 14, 2024 BioInsights

Chapters

Key recent deals and funding stories in CGT biotech: Karuna Therapeutics, Cerevel Therapeutics, Gracell Biotech, CG Oncology, Kyverna Therapeutics

Key recent deals and funding stories in CGT biotech: Metagenomi

Key recent deals and funding stories in CGT biotech: Tome Biosciences.

Key recent deals and funding stories in CGT biotech: Beam Therapeutics, Caribou Biosciences

The story of Casgevy’s approval

The story of Roctavian’s approval

Sarepta Therapeutics

How do you view the CAR-T cell therapy space, both currently and moving forward?

Any other highlights from JP Morgan week 2024?

The BioInsights Podcast

Insights into advanced therapies in the context of evolving funding and M&A environments

Jun 14, 2024

BioInsights

David McCall, Senior Editor, BioInsights, spoke to Lee Brown, Healthcare Sector Global Team Leader, Third Bridge Group, on Tuesday, February 6, 2024 to gain his insights into the fast-moving market landscape of advanced therapies. The discussion outlines key recent news and strategic moves from prominent pharma and biotech companies in the field, as well as the prospects for specific technologies such as CRISPR-based genome editing and next-generation CAR-T therapies.

Share Episode

Share on Facebook Share on Twitter Share on LinkedIn Download

Subscribe

Apple Podcasts Spotify More

Listen on

Apple Podcasts Spotify Amazon Music Overcast Castro Castbox +

Share Episode

Share on Facebook Share on Twitter Share on LinkedIn

David McCall, Senior Editor, BioInsights, spoke to Lee Brown, Healthcare Sector Global Team Leader, Third Bridge Group, on Tuesday, February 6, 2024 to gain his insights into the fast-moving market landscape of advanced therapies. The discussion outlines key recent news and strategic moves from prominent pharma and biotech companies in the field, as well as the prospects for specific technologies such as CRISPR-based genome editing and next-generation CAR-T therapies.